CSV June 29, 2020 through June 29, 2022 See all Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PACKAGING	GENERAL	*Second*	Online	26-Mar-2021	1-Dec-2025	*NA*	*NA*	In *Light-*

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AND STORAGE RE QUIREMENTS	*Packaging Definitions*	*Supplement to USP43–NF38*						*resistant container*: Change ?661.2?, *Functionality, Spectral Transmission Requirements for Light-Resistant Components and Systems.* to: ?661.2?, *Functionality Test Method, Spectral Transmission Requirements for Light-Resistant Components and Systems*.
GADOTERATE MEGLUMINE INJECTION	OTHER COMP ONE NTS/*Content of Meglumine*	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change Result = (*a*/*?*) × (1/*l*) × (1/*L*) × 100 to: Result = (*a*/*?*) × 100 × (1/*l*) ×

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(1/*L*) × 100
DICLOFENAC POTASSIUM	IDENTIFICATION/*C.*	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *Sample solution*: Change 7 N hydrochloride acid to: 7 N hydrochloric acid
DACARBAZINE FOR INJECTION	IMPURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	Delete *Diluent*: 4.0 mg/mL of citric acid in water
SORAFENIB TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In *Tolerances*: Change NLT 75 (*Q*) of the labeled amount of sorafenib ($C_{21}H_{16}ClF_3N_4O_3$) is dissolved. to: NLT 75% (*Q*) of the labeled amount of sorafenib ($C_{21}H_{16}ClF_3N_4O_3$) is dissolved.
FLUOCINOLONE ACETONIDE	*Organic Impurities*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *Acceptance criteria*/*Total*

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								impurities: Change NMT 2.5%. Disregard any peak below 0.05% of the peak area of fluocinolone acetonide from the *Standard solution*. to: NMT 2.5%. Disregard any peak below 0.05% of the peak area of fluocinolone acetonide from the *Sample solution*.
TRYPTOPHAN	ADDITIONAL REQUIREMENTS/*USP Reference Standards ?11?*	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In USP Tryptophan Related Compound A RS: Change 3,3?-[Ethylidene bis(1*H*-indole-1,3-diyl)] bis[2*S*)-2-aminopropa

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								noic]acid. $C_{24}H_{26}N_4O_4$ 432.49 to: (2*S*,2'*S*)-3,3'-[Ethane-1,1-diyl bis(1*H*-indole-1,3-diyl)] bis(2-aminopropanoic acid). $C_{24}H_{26}N_4O_4$ 434.50
CARVEDILOL	ADDITIONAL REQUIREMENTS/*USP Reference Standards*	*USP43–NF38*	Online	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In USP Carvedilol Related Compound A RS: Change 629.74 to: 629.75 AND In USP Carvedilol Related Compound B RS: Change 645.74 to: 645.76 AND

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								In USP Carvedilol Related Compound C RS: Change 496.60 to: 496.61 AND In USP Carvedilol Related Compound E RS: Change 2-(2-Methoxyphenoxy)ethylamine. $C_9H_{13}NO_2$ 167.21 to: [Note—This material may be available in the free base or salt form.] 2-(2-Methoxyphenoxy)ethylamine. $C_9H_{13}NO_2$ 167.21 2-(2-Methoxyph

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								enoxy)ethyl amine hydrochloride monohydrate. $C_9H_{13}NO_2$? HCl ? H_2O 221.68 AND In USP Carvedilol System Suitability Mixture RS: Change Mixture of approximately 0.1% carvedilol related compound F (1-(2-(2-Methoxyphenoxy)ethylamino)-3-(2,3,4,9-tetra hydro-1*H*-carbazol-5-yloxy)propan-2-ol) in a matrix of carvedilol drug substance. to: Contains a mixture of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								carvedilol related compound F in a matrix of carvedilol drug substance: Carvedilol. Carvedilol related compound F. [Note—This material may be available in the free base or salt form.] 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(2,3,4,9-tetrahydro-1*H*-carbazol-5-yloxy)propan-2-ol. $C_{24}H_{30}N_2O_4$ 410.51 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(2,3,4,9-tetrahydro-1*H*

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-carbazol-5-yloxy)propan-2-ol acetate. $C_{24}H_{30}N_2O_4$? $C_2H_4O_2$ 470.57
MIRTAZAPINE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	Online	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In USP Mirtazapine Resolution Mixture RS: Change Impurity D: 1,2,3,4,10,14b-Hexahydropyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine. to: Impurity D: [Note–This impurity may be available either as the free base form or as the hydrochloride salt form.] 1,2,3,4,10,14b-Hexahydropyrazino[2,1-*a*]pyri

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								do[2,3-*c*][2]benzazepine or 1,2,3,4,10,14b-Hexahydropyrazino[2,1-*a*]pyri do[2,3-*c*][2]benzazepine hydrochloride.
QUETIAPINE EXTENDED-RELEASE TABLETS	ASSAY/ *Procedure*/*System Suitability*	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *Resolution*: Change NLT 2.0 between the quetiapine desthoxy and quetiapine peaks; *System suitability solution* to: NLT 2.0 between the quetiapine desethoxy and quetiapine peaks; *System suitability solution*
SUCCINYLCHOLINE	ADDITIONAL REQUIREMENT	*USPNF 2021 ISSUE 1*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	In USP Succinylmonocholine

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CHLORIDE	S/*USP Reference Standards <11>*							Chloride RS: Change Ethanaminium, 2-(carboxy-1-oxopropoxy)-*N*,*N*,*N*-trimethyl-, chloride. to: Ethanaminium, 2-(3-carboxy-1-oxopropoxy)-*N*,*N*,*N*-trimethyl-, chloride; Also known as 2-[(3-Carboxypropanoyl)oxy]-*N*,*N*,*N*-trimethylethan-1-aminium chloride.
PANTOPRAZOLE SODIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In USP Pantoprazole Related Compound E RS: Change A mixture of the stereoisomers

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of 6,6?-bis(difluoromethoxy)-2,2?-bis[[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl]-1*H*,1?*H*-5,5?-bibenzimidazolyl. to: 6,6?-Bis(difluoromethoxy)-2,2?-bis[[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl]-1*H*,1?*H*-5,5?-bibenzimidazole.
ATRACURIUM BESYLATE	CHEMICAL INFORMATION	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	Change 2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimeth oxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester to:

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester
PACLITAXEL INJECTION	TITLE	*USPNF 2021 ISSUE 1*	Online	26-Feb-2021	1-May-2021	*NA*	*NA*	Change Paclit 1axel Injection to: Paclitaxel Injection
TIAGABINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards* <11>	*USPNF 2021 ISSUE 1*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	In USP Tiagabine Hydrochloride RS: Delete [NOTE—Available in monohydrate form.]
ONDANSETRON HYDROCHLORIDE	*USP Reference standards* <11>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								methyl- 4*H* -carbazol-4-one hydrochloride. to: 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H* -carbazol-4-one hydrochloride. AND In USP Ondansetron Related Compound C RS: Change 1,2,3,9-Tetrahyd ro- 9-me thyl-4*H* -carbazol-4-one . to: 9-Methyl-1,2,3,9-tet rahydr o-4*H* -carbazol-4-one

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								. AND In USP Ondansetron Related Compound D RS: Change 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one. to: 9-Methyl-3-methylene-1,2,3,9-tetrahydro-4*H*-carbazol-4-one.
DACARBAZINE FOR INJECTION	IMPURITIES	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	Delete *Limit of 2-Azahypoxanthine* test
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In *Buffer*: Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to:

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Adjust with phosphoric acid to a pH of 6.4 ± 0.1.
MINOXIDIL TABLETS	IMPURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	In *Analysis*: Change Result = (r_U/r_S) × (C_U/C_S) × 100 to: Result = (r_U/r_S) × (C_S/C_U) × 100
CETIRIZINE HYDROCHLORIDE	IMPURITIES/*Residue on Ignition* ?281?	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	Delete Sample: 1 g
ISOPROTERENOL HYDROCHLORIDE INJECTION	*Color and clarity*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	Change Using the Injection as the *Test solution*, proceed as directed for *Color and clarity* under *Isoproterenol Inhalation Solution*. to: *Standard solution* —Transfer 2.0

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mL of 0.100 N iodine VS to a 500-mL volumetric flask, dilute with water to volume, and mix. *Proce dure*—Visually examine a portion of the Injection (*Test solution*) in a suitable clear glass test tube against a white background: it is not pinkish and it contains no precipitate. If any yellow color is observed in the *Test solution*, concomitantly determine the absorbances of the *Test solution* and the *Standard solution* in 1-cm

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								cells with a suitable spectro photometer set at 460 nm: the absorbance of the *Test solution* does not exceed that of the *Standard solution*.
FULVESTRANT	CHEMICAL INFORMATION	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	Change 606.77 to: 606.78
DIMENHYDRINATE TABLETS	OTHER COMPONENTS/ *8-Chlorotheophylline*	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	In *Analysis*: Change C_U = nominal concentration of dimenhydrinate in the *Sample solution* (mg/mL) to: C_U = determined concentration of dimenhydrinate in the *Sample solution*, as obtained in the *Assay* (mg/mL)

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION	1. PRELIMINARY ASSESSMENT	*Second Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In paragraph 4 of *1.4 Choosing an apparatus*: Change peak vessels to: apex vessels
CARVEDILOL	IM PURITIES/*Organic Impurities, Procedure 2*	*USP43–NF38*	Online	18-Dec-2020	1-Jan-2021	*NA*	*NA*	In *Table 3*/footnote b: Change 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(6,7,8,9-tetrahydro-5*H*-carbazol-4-yloxy)propan-2-ol. to: 1-(2-(2-Methoxyphenoxy)ethylamino)-3-(2,3,4,9-tetrahydro-1*H*-carbazol-5-yloxy)propan-2-ol.
MIRTAZAPINE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference*	*USP43–NF38*	Online	26-Mar-2021	1-Apr-2021	*NA*	*NA*	In USP Mirtazapine Resolution Mixture RS:

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Standards <11>							Change Impurity D: 1,2,3,4,10,14b-Hexahydropyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine. to: Impurity D: [Note–This impurity may be available either as the free base form or as the hydrochloride salt form.] 1,2,3,4,10,14b-Hexahydropyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine or 1,2,3,4,10,14b-Hexahydropyrazino[2,1-*a*]pyrido[2,3-*c*][2]benzazepine

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride.
DACTINOMYCIN	CHEMICAL INFORMATION	*USP43–NF38*	Online	25-Jun-2021	1-Jul-2021	*NA*	*NA*	Please see the updated chemical structure at online.uspnf.com
QUETIAPINE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities/System Suitability*	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *Resolution*: Change NLT 2.0 between the quetiapine desthoxy and quetiapine peaks to: NLT 2.0 between the quetiapine desethoxy and quetiapine peaks
ONDANSETRON	*USP Reference standards <11>*	*USPNF 2021 ISSUE 1*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	Change USP Ondansetron RS USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								d ro- 9-me thyl-4*H* -carbazol-4-one . USP Ondansetron Related Compound D RS 1,2,3,9-Tetrahy dro-9-methyl-3- met hylene- 4*H* -carbazol-4-one . to: USP Ondansetron RS USP Ondansetron Related Compound A RS 3-[(Dimethylami no)methyl]-9-m ethyl-1,2,3,9-tet rahydr

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								o-4*H*-carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 9-Methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one. USP Ondansetron Related Compound D RS 9-Methyl-3-methylene-1,2,3,9-tetrahydro-4*H*-carbazol-4-one.
ONDANSETRON ORAL SOLUTION	*USP Reference standards <11>*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	Change USP Ondansetron Related Compound A RS

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 1,2,3,9-Tetrahydro-9-methyl-4*H*-carbazol-4-one. USP Ondansetron Related Compound D RS 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one.

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: USP Ondansetron Related Compound A RS 3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. USP Ondansetron Related Compound C RS 9-Methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one. USP Ondansetron Related Compound D RS 9-Methyl-3-methylene-1,2,3,9-t

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								etra hydro-4*H* -carbazol-4-one .
IVERMECTIN	CHEMICAL INFORMATION	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	Change $C_{48}H_{74}O_{14}$ (Component H_2B_{1a}) 875.09 $C_{47}H_{72}O_{14}$ (Component H_2B_{1b}) 861.07 Component H_2B_{1a}: Avermectin A_{1a}, 5-*O* -demethyl-22,23 -dihydro-. (2a*E*,4*E*,8*E*)-(5?*S*,6*S*,6?*R* ,7*S*,11*R*,13*R* ,15*S*,17a*R* ,20*R*,20a*R* ,20b*S*)-6?-(*S*)-*sec* -Butyl-3?,4?,5?, 6,6?,7,10,11,14, 15,17a,20,20a,2 0b-tetradecahyd ro-20,20b-dihyd roxy[11,15-meth ano-2*H*,13*H*

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2?-[2*H*]pyran]-7-yl 2,6-di deoxy-4-*O* *O*-methyl-?-L-*arabino*-hexopyranosyl)-3-*O*-methyl-?-L-*arabino*-hexopyranoside CAS RN®: 70161-11-4. Component H_2B_{1b}: Avermectin A_{1a}, 5-*O*-demethyl-25-de(1-methylpropy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								l)-22,23-dihydro-25-(1-methylethyl)-. (2a*E*,4*E*,8*E*)-(5?*S*,6*S*,6?*R*,7*S*,11*R*,13*R*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-3?,4?,5?,6,6?,7,10,11,-oxospiro[11,15-methano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2?[2*H*]pyran]-7-yl 2,6-dideoxy-4-*O*-methyl-?-L-*arabino*-hexopyranosyl)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-3-*O*-methyl-?-L-*arabino*-hexopyranoside CAS RN®: 70209-81-3; UNII: 0W28CYI3TU. to: $C_{48}H_{74}O_{14}$ (Component H_2B_{1a}) 875.11 $C_{47}H_{72}O_{14}$ (Component H_2B_{1b}) 861.08 Component H_2B_{1a}: Avermectin A_{1a}, 5-*O*-demethyl-22,23-dihydro-. (2a*E*,4*E*,8*E*)-(5'*S*,6*S*,6'*R*,7*S*,11*R*,13*R*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-6'-(*S*)-*sec*-Butyl-3',4',5',6,6',7,10,11,14,15,17a,20,20a,2

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								0b-tetradecahydro-20,20b-dihydroxy-5’,6,8,19-tetramethyl-17-oxospiro [11,15-meth ano-2*H*,13*H* ,17*H* -furo[4,3,2-*pq*][2,6]benzodioxacyclooctadecin -13,2’-[2*H*]pyran]-7-yl 2, 6-di deoxy- 4-*O*
								O -me thyl-?- L- *arabino* -hexopyranosyl) -3-*O*-methyl-?- L- *arabino* -hexopyranoside CAS RN®:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								71827-03-7; UNII: 91Y2202OUW. Component H_2B_{1b}: Avermectin A_{1a}, 5-*O* -demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)-. (2a*E*,4*E*,8*E*)-(5'*S*,6*S*,6'*R*,7*S*,11*R*,13*R*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-3',4',5',6,6',7,10,11,14,15,17a,20,20a,20b-Tetradecahydro-20,20b-dihydroxy-6'-isopropyl-5',6,8,19-tetramethyl-17-oxospiro [11,15-methano-2*H*,13*H*,17*H*-furo[4,3,2-*pq*

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								][2,6]benzodioxacyclooctadecin-13,2’-[2*H*]pyran]-7-yl 2,6-di deoxy-4-*O*
AMLODIPINE AND OLMESARTAN MEDOXOMIL TABLETS	IMPURITIES/*Organic Impurities*	*USP43–NF38*	Online	26-Feb-2021	1-Mar-2021	*NA*	*NA*	*O*-methyl-?-L-*arabino*-hexopyranosyl)-3-*O*-methyl-?-L-*arabino*-hexopyranoside CAS RN®: 70209-81-3; UNII: 0W28CYI3TU. In the first variable definition list in *Analysis*: Change 522.93 to:

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AMITRIPTYLINE HYDROCHLORIDE	CHEMICAL INFORMATION	*USP43–NF38*	Online	28-May-2021	1-Jun-2021	*NA*	*NA*	522.94 Change 313.86 to: 313.87
ALFUZOSIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*USPNF 2021 ISSUE 1*	Online	29-Oct-2021	1-Nov-2021	*NA*	*NA*	In *Analysis*: Change r_S = peak response of alfuzosin from the *Sample solution* to: r_S = peak response of alfuzosin from the *Standard solution*
ONDANSETRON INJECTION	*USP Reference standards* <11>	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In USP Ondansetron Related Compound A RS: Change 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one hydrochloride. AND In USP Ondansetron Related Compound C RS: Change 1,2,3,9-Tetrahyd ro-9-methyl-4*H*-carbazol-4-one. to: 9-Methyl-1,2,3,9-tet rahydro-4*H*-carbazol-4-one. AND In USP Ondansetron Related

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Compound D RS: Change 1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one. to: 9-Methyl-3-methylene-1,2,3,9-tetrahydro-4*H*-carbazol-4-one.
MUPIROCIN CREAM	*Related compounds*/*Table 1*	*USPNF Online*	Online	29-Apr-2022	1-May-2022	*NA*	*NA*	In footnote 2: Change 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*,8a*RS*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyl

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oxy}nonanoic acid. to: 9-{(*E*)-4-[(2*R*,3a*S*,6*S*,7*S*)-2-{(1*RS*,2*S*,3*S*)-1,3-Dihydroxy-2-methylbutyl}-7-hydroxyhexahydro-2*H*-furo[3,2-*c*]pyran-6-yl]-3-methylbut-2-enoyloxy}nonanoic acid.
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE TABLETS	IMPURITIES/*Limit of Homatropine Hydrobromide and Related Substances*	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In *Buffer*: Change Adjust with phosphoric acid to a pH of 6.4 ± 0.01. to: Adjust with phosphoric acid to a pH of 6.4 ± 0.1.
AMIODARONE HYDROCHLOR	ADDITIONAL REQUIREMENT	*USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	In USP Amiodarone

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IDE	S/*USP Reference Standards <11>*							Related Compound H RS: Change 2-Chloro-*N*,*N*-diethylethanamine. $C_6H_{14}ClN$ 135.64 to: 2-Chloro-*N*,*N*-diethylethanamine hydrochloride. $C_6H_{14}ClN \cdot HCl$ 172.09
SERTRALINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	26-Mar-2021	1-May-2021	*NA*	*NA*	In USP Sertraline Hydrochloride Racemic Mixture RS: Change $C_{17}H_{17}Cl_2 \cdot HCl$ to: $C_{17}H_{17}Cl_2N \cdot HCl$
RIFABUTIN	IMPURITIES/*Organic Impurities,*	*USPNF 2021 ISSUE 1*	Online	27-Aug-2021	1-Sep-2021	*NA*	*NA*	In *Sample solution*: Change 1 mg/mL of

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Procedure 2							USP Rifabutin RS prepared as follows. to: 1 mg/mL of Rifabutin prepared as follows.
CAPTOPRIL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USPNF 2021 ISSUE 1*	Online	19-Nov-2021	1-Dec-2021	*NA*	*NA*	In USP Captopril Disulfide RS: Change L-Proline, 1,1?-[dithiobis(2-methyl-1-oxo-3,1-propanediyl)]bis-[*S*-(*R**,*R**)]-. to: (2?*S*)-[(2*S*,2?*S*)-3,3?-Disulfanediylbis(2-methylpropanoyl)]di-L-proline.
FULVESTRANT	*Related compounds*	*USPNF Online*	Online	28-Jan-2022	1-Feb-2022	*NA*	*NA*	In footnote 1 of table: Change Estra-1,3,5(10)-triene-6-one-3,17-diol,7-[9-[(4,4,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								5,5,5-pentafluoropentyl)sulfinyl]nonyl]-(7?,17?) to: 7?-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-6-one-3,17?-diol AND In footnote 2: Change Estra-1,3,5(10),6-tetraene-3,17-diol,7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-(7?,17?) to: 7-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10),6-tetraene-3,17?-diol AND In footnote 3: Change Estra-1,3,5(10)-triene-3,17-diol,

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfonyl]nonyl]-(7?,17?) to: 7?-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfonyl]nonyl}estra-1,3,5(10)-triene-3,17?-diol AND In footnote 4: Change Estra-1,3,5(10)-triene-3,17-diol, 7-{9-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonylsulfinyl]nonyl}-(7?,17?) to: 7?-{9-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonylsulfinyl]nonyl}estra-1,3,5(10)-triene-3,17?-diol AND In footnote 5:

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change 7,7-Nonamethylene-bis(estra-1,3,5(10)-triene-3,17-diol-(7?,17?) to: 7?,7?-Nonamethylenebis[estra-1,3,5(10)-triene-3,17?-diol] AND In footnote 6: Change Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-(7?,17?) to: 7?-{9-[(4,4,5,5,5,-Pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17?-diol
RIFABUTIN	CHEMICAL INFORMATION	*USPNF Online*	Online	27-May-2022	1-Jun-2022	*NA*	*NA*	Change 847.00 to: 847.02 AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change (9*S*,12*E*,14*S*,15*R*,16*S*,17*R*,18*R*,19*R*,20*S*,21*S*,22*E*,24*Z*)-6,16,18,20-Tetrahydroxy-1?-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethylspiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2*H*-furo[2?,3?:7,8]naphth[1,2-*d*]imidazole-2,4?-piperidine]-5,10,26-(3*H*,9*H*)-trione-16-acetate to: (9*S*,12*E*,14*S*,15*R*,16*S*,17*R*,18*R*,19*R*,20*S*,21*S*,22*E*,24*Z*)-6,18,20-Trihydroxy-1’-isobutyl-14-methoxy-7,9,15,17,19,21,2

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PLASTIC PACKAGING SYSTEMS FOR PHARMACEUTICAL USE	SCOPE/*Table 1*	*First Supplement to USP43–NF38*	Online	20-Nov-2020	1-Dec-2020	*NA*	*NA*	5-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2*H*-furo[2',3':7,8]naphtho[1,2-*d*]imidazole-2,4'-piperidin]-16-yl acetate Change If light protection is necessary[c] to: If light protection is necessary AND Change Row 11 Chemical Suitability for Use Assessment Risk-based testing Risk-based testing to:

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FENTANYL	CHEMICAL INFORMATION	*USP43–NF38*	Online	18-Dec-2020	1-Jan-2021	*NA*	*NA*	Chemical Suitability for Use Assessment Risk-based testing Risk-based testing Functionality Change 336.47 to: 336.48
AZITHROMYCIN FOR ORAL SUSPENSION	PERFORMANCE TESTS/ *Dissolution <711>*	*USPNF 2021 ISSUE 1*	Online	30-Apr-2021	1-May-2021	*NA*	*NA*	In *Medium*: Change Sodium phosphate buffer, pH of 6.0 (14.2 g/L of disodium hydrogen orthophosphate anhydrous in *water*, adjusted with dilute hydrochloric acid to a pH of 6.0) to: Sodium phosphate buffer, pH 6.0

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(14.2 g/L of sodium phosphate, dibasic, anhydrous in water, adjusted with dilute hydrochloric acid to pH 6.0) AND In *Solution A*: Change orthophosphoric acid to: phosphoric acid
ANALYTICAL METHODOLOGIES BASED ON SCATTERING PHENOMENA—GENERAL	1. OVERVIEW: GENERAL CHAPTERS BASED ON SCATTERING PHENOMENA	*USPNF 2021 ISSUE 1*	Online	24-Sep-2021	1-Oct-2021	*NA*	*NA*	In *Table 1*: Change ?1430.6?[a] to: ?1430.6? AND Change ?1430.7?[a] to: ?1430.7? AND Delete footnote a
EXTENDED PHENYTOIN	ASSAY/ *Procedure*	*Revision Bulletin (Official*	Online	31-Dec-2021	1-Jan-2022	*NA*	*NA*	In *Sample solution*:

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM CAPSULES		*March 01, 2021)*						Change Nominally 0.6 mg/mL of phenytoin to: Nominally 0.6 mg/mL of phenytoin sodium AND In *Analysis*: Change C_U = nominal concentration of phenytoin in the *Sample solution* (mg/mL) to: C_U = nominal concentration of phenytoin sodium in the *Sample solution* (mg/mL)
ONDANSETRON TABLETS	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	25-Mar-2022	1-Apr-2022	*NA*	*NA*	In *Table 1*/footnotes: Change [b] 1,2,3,9-Tetrahydro-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								9-methyl-4*H*-carbazol-4-one.[c]
								1,2,3,9-Tetrahydro-9-methyl-3-methylene-4*H*-carbazol-4-one.[d]
								3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one.[e]
								1,2,3,9-Tetrahydro-9-methyl-3-[1*H*-imidazol-1-yl)methyl]-4*H*-carbazol-4-one. to:[b]
								9-Methyl-1,2,3,9

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-tetrahydro-4*H*-carbazol-4-one.[c]
								9-Methyl-3-methylene-1,2,3,9-tetrahydro-4*H*-carbazol-4-one.[d]
								3-[(Dimethylamino)methyl]-9-methyl-1,2,3,9-tetrahydro-4*H*-carbazol-4-one.[e]
DOXYCYCLINE CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference*	*USPNF Online*	Online	24-Jun-2022	1-Jul-2022	*NA*	*NA*	In USP Doxycycline Related Compound A

Monograph Title	Section	Source Publication	Page Number Sort descending	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Standards <11>							RS: Change 444.43 to: 444.44 AND Change (4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride. $C_{22}H_{24}N_2O_8$ · HCl 480.13 to: (4*S*,4a*R*,5*S*,5a*R*,6*S*,12a*S*)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1-dioxo-2-naphthacenecarboxamide hydrochloride. $C_{22}H_{24}N_2O_8$ · HCl 480.90

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2
- Page 3
- Current page 4
- Page 5
- Page 6
- Page 7
- Next page Next ›
- Last page Last »